版本:
中国

BRIEF-Array BioPharma and Bristol-Myers Squibb announce strategic collaboration

May 30 Array BioPharma Inc

* Array bioPharma and Bristol-Myers Squibb announce strategic collaboration

* Bristol-Myers Squibb Co says under terms of agreement, Array and Bristol-Myers Squibb will jointly support study with Array acting as sponsor

* Bristol-Myers Squibb Co - Collaboration to investigate safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib

* Bristol-Myers Squibb Co says phase 1/2 study is expected to establish recommended dose regimens for further study

* Bristol-Myers Squibb Co says results from phase 1/2 study, which is anticipated to begin in second half of 2017

* Bristol-Myers Squibb Co - Collaboration to investigate binimetinib with co's opdivo (nivolumab) and opdivo + yervoy (ipilimumab) regimen

* Bristol-Myers Squibb Co - Collaboration for potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐